ACVR1 and fibrodysplasia ossificans progressiva: All of them derive from research on FOP pathophysiology and, because the cause of the disease is a mutation in the ACVR1 gene, encoding the Alk2 receptor for Bone Morphogenetic Proteins (BMPs), which induces an anomalous activation of signaling, the majority of the proposed therapeutic strategies are focused on the inhibition of BMP signaling.